MapLight Therapeutics
Market cap $365M 55.6M shares (vendor count, Nov 18, 2026) × $6.57 close Nov 17, 2026 · share count from the market-data vendor, not the SEC cover page
Most recent annual filing: 2026-03-26
- ML-055 next-gen M1 corporate update2026ML-055 next-gen M1 corporate update, 2026, routine
- ML-009 PAM corporate update2027ML-009 PAM corporate update, 2027, routine
- ML-021 M4 antagonist corporate update2027ML-021 M4 antagonist corporate update, 2027, routine
- ML-007C-MA VISTA Ph2 topline2H 2027ML-007C-MA VISTA Ph2 topline, 2H 2027, thesis-defining
- ZEPHYR-2 Study 311 topline2028ZEPHYR-2 Study 311 topline, 2028, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
zolmitriptan
ML-004Technology platforms
MapLight Discovery Platform
Circuit-based CNS drug discovery platform combining optogenetics, single-cell transcriptomics, and STARmap spatial transcriptomics to identify neural circuits causally linked to CNS disease symptoms and discover druggable targets within those circuits for therapeutic modulation.
Discontinued (3)
- ML-009 — undisclosed · strategic deprioritization under current operating plan
- ML-055 — undisclosed · strategic deprioritization under current operating plan
- ML-021 — Parkinson's Disease · strategic deprioritization under current operating plan
Capital (as filed)
- Cash
- $55.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $229M Sep 30, 2026
- Long-term investments
- $179M Sep 30, 2026
- Operating cash flow
- −$35.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $463M cash, runway 2028 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-09-23 424B3 · Resale (selling stockholders)
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (6)
- 2026-11-17 UPDATE: MapLight Therapeutics (MPLT) - An ATM Below Cash 🔒 Paid
- 2026-08-19 UPDATE: MapLight Therapeutics (MPLT) - Catalyst4 Bought the Deal 🔒 Paid
- 2026-08-14 UPDATE: MapLight Therapeutics (MPLT) - The Missing Endpoint Shows Up 🔒 Paid
- 2026-08-05 UPDATE: MapLight Therapeutics (MPLT) - Now We Know Who Bought It 🔒 Paid
- 2026-07-31 UPDATE: MapLight Therapeutics (MPLT) - Somebody Sold the Bounce 🔒 Paid
- 2026-07-28 MapLight Therapeutics (MPLT) — Scientific Deep Dive for ML-007C-MA, ML-004, and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (6 calls)
Every verdict Biotech Distilled has published on MapLight Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-07-28 Watch MapLight Therapeutics (MPLT) — Scientific Deep Dive for ML-007C-MA, ML-004, and Pipeline Products ZEPHYR met its primary endpoint but delivered a weak effect size (0.37), the QD arm failed contradicting the company's own PK/PD model, the negative-symptom key secondary went unreported, composition-of-matter patents expire 2031–2032, and the balance sheet cannot fund a confirmatory Phase 3 to readout.
- 2026-07-31 Watch UPDATE: MapLight Therapeutics (MPLT) - Somebody Sold the Bounce Novo Holdings dumped ~1.6M shares into the post-ZEPHYR bounce, thinning the specialist crossover book further; the four unresolved scientific questions are unchanged and the supply overhang now has a named clearing price of $12.00.
- 2026-08-05 Speculative buy speculative UPDATE: MapLight Therapeutics (MPLT) - Now We Know Who Bought It Catalyst4 committed ~$15.3M of working capital at ~$12.65 average to reach 47.9%, providing a named funded buyer against the supply overhang, while roughly half the market cap remains cash and VISTA offers a separate shot on goal in an indication with zero approved therapies.
- 2026-08-14 Hold UPDATE: MapLight Therapeutics (MPLT) - The Missing Endpoint Shows Up The $150M raise at $11.38 clears the financing overhang and extends runway through 2028, but the disclosed PANSS negative Marder factor (ES 0.18, p=0.244) confirms the July silence was a miss, and the raise appears to be a marketed deal without insider participation — close to the reversal condition set on August 4.
- 2026-08-19 Speculative buy speculative UPDATE: MapLight Therapeutics (MPLT) - Catalyst4 Bought the Deal Catalyst4 funded 55.6% of the $150M PIPE at $11.38 and reached 49.9%, meaning the raise was insider-anchored rather than a marketed deal — negating the reversal condition set on August 4 — while cash now runs through 2028 covering both VISTA and ZEPHYR-2.
- 2026-11-17 Hold UPDATE: MapLight Therapeutics (MPLT) - An ATM Below Cash MapLight filed a $100M ATM below cash per share, T. Rowe has sold most of its stake, the EOP2 meeting remains unscheduled, and the Phase 3 now reads out in 2028 — both conditions for reversal are moving the wrong way, though the stock trading at or below cash and Deep Track's entry limit the downside.
- Long call · opened Aug 5, 2026 at $12.92 · -49.1% vs XBI -5.1% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“We are also conducting VISTA, a Phase 2 trial evaluating ML-007C-MA for the treatment of ADP, and we expect to report topline results in the second half of 2027.”
matched to ML-007C-MA (Alzheimer's disease psychosis, VISTA) · topline data
-
-
-
“We are also conducting VISTA, a Phase 2 trial evaluating ML-007C-MA for the treatment of ADP, and we expect to report topline results in the second half of 2027.”
matched to ML-007C-MA (Alzheimer's disease psychosis, VISTA) · topline data
-
-
-
“We are also conducting VISTA, a Phase 2 trial evaluating ML-007C-MA for the treatment of ADP, and we expect to report topline results in the second half of 2027.”
matched to ML-007C-MA (Alzheimer's disease psychosis, VISTA) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (29)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 2026S-3Shelf registration→ BD updateSummary on the 8-K
- Nov 16, 2026ReleaseMapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update→ BD updateSummary on the 8-K
- Nov 16, 20268-KCurrent report: material agreement→ BD updateMapLight quietly opened a $100M ATM facility with Leerink today — and T. Rowe Price cut its stake by ~66%, from 6.17% to 1.7%, while the market wasn't watching. Two new overhang sources hit simultaneously, right as ZEPHYR-2 gets a formal 2028 timeline.
- Nov 16, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateSummary on the 8-K
- Nov 16, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 6, 2026ReleaseMapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
- Sep 23, 2026424B3Prospectus (resale / update)
- Sep 18, 2026S-1/ARegistration statement (amended)
- Sep 9, 2026S-1Registration statement
- Sep 9, 2026ReleaseMapLight Therapeutics to Participate in Upcoming Investor Conference
- Aug 18, 2026SCHEDULE 13D/A13D amendment
- Aug 13, 2026ReleaseMapLight Therapeutics Announces $150 Million Private Placement Financing
- Aug 13, 2026ReleaseMapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- Aug 13, 20268-KCurrent report: material agreement, results of operations, unregistered sale of equity · EX-99.1BD extracted 2 program updates from this document → MPLT pipeline
- Aug 13, 202610-QQuarterly report
- Aug 3, 2026SCHEDULE 13D/A13D amendment
- Jul 31, 2026SCHEDULE 13D/A13D amendment
- Jul 27, 2026ReleaseMapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
- Jul 27, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 2 program updates from this document → MPLT pipeline
- Jun 24, 20268-KCurrent report: shareholder vote
- Jun 22, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Jun 18, 20268-KCurrent report: officer / director change
- May 14, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- May 14, 202610-QQuarterly report
- Apr 29, 2026DEFA14AProxy soliciting material
- Apr 29, 2026DEF 14AProxy statement
- Apr 29, 20268-KCurrent report: officer / director change
- Mar 26, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- Mar 26, 202610-KAnnual report
9 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 17, 2026EFFECTRegistration effective
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Nov 16, 2026SCHEDULE 13G/A13G amendment→ BD updateSummary on the 8-K
- Nov 16, 2026POS AMPost-effective amendment→ BD updateSummary on the 8-K
- Sep 23, 2026EFFECTRegistration effective
- Aug 20, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- Apr 29, 2026ARSAnnual report to shareholders
- Mar 26, 2026S-8Employee plan registration